炎症性肠病生物治疗的最新研究进展

被引：10

作者：

郑雅丹 ^{[1
]}

李岭 ^{[1
]}

庞智 ^{[2
]}

机构：

[1] 苏州大学附属第一医院消化内科

[2] 南京医科大学附属苏州医院(北区)消化内科

来源：

胃肠病学和肝病学杂志 | 2020年 / 29卷 / 02期

关键词：

炎症性肠病; 生物制剂; 治疗; 安全性;

D O I：

暂无

中图分类号：

R574 [肠疾病];

学科分类号：

100201 [内科学];

摘要：

近年关于炎症性肠病(inflammatory bowel disease,IBD)的病因及发病机制方面研究有了显著进展,生物制剂的应用使其病情进展和疾病转归得到了新转折。目前针对不同的分子通路,已经开发出多种治疗IBD的新型生物制剂,本文主要介绍目前新出现的主要的治疗IBD的生物制剂的有效性和安全性。

引用

页码：212 / 218

页数：7

共 22 条

[1]

细胞因子在炎症性肠病治疗中的研究进展 [J].

张婷 ;

崔伯塔 ;

张发明 .

胃肠病学和肝病学杂志, 2016, 25 (07) :724-728

[2]

Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis [J].

Sandborn, William J. ;

Cyrille, Marcoli ;

Hansen, Mark Berner ;

Feagan, Brian G. ;

Loftus, Edward V., Jr. ;

Rogler, Gerhard ;

Vermeire, Severine ;

Cruz, Martha L. ;

Yang, Jun ;

Boedigheimer, Michael J. ;

Abuqayyas, Lubna ;

Evangelista, Christine M. ;

Sullivan, Barbara A. ;

Reinisch, Walter .

GASTROENTEROLOGY, 2019, 156 (04) :946-+

[3]

Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn's Disease [J].

Panes, Julian ;

Garcia-Olmo, Damian ;

Van Assche, Gert ;

Colombel, Jean Frederic ;

Reinisch, Walter ;

Baumgart, Daniel C. ;

Dignass, Axel ;

Nachury, Maria ;

Ferrante, Marc ;

Kazemi-Shirazi, Lili ;

Grimaud, Jean C. ;

de la Portilla, Fernando ;

Goldin, Eran ;

Paule Richard, Marie ;

Carmen Diez, Mary ;

Tagarro, Ignacio ;

Leselbaum, Anne ;

Danese, Silvio .

GASTROENTEROLOGY, 2018, 154 (05) :1334-+

[4]

Systematic review with meta-analysis: the efficacy and safety of stem cell therapy for Crohn’s disease.[J].Yun Qiu;Man-ying Li;Ting Feng;Rui Feng;Ren Mao;Bai-li Chen;Yao He;Zhi-rong Zeng;Sheng-hong Zhang;Min-hu Chen.Stem Cell Research & Therapy.2017, 1

[5]

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study [J].

Sands, Bruce E. ;

Chen, Jingjing ;

Feagan, Brian G. ;

Penney, Mark ;

Rees, William A. ;

Danese, Silvio ;

Higgins, Peter D. R. ;

Newbold, Paul ;

Faggioni, Raffaella ;

Patra, Kaushik ;

Li, Jing ;

Klekotka, Paul ;

Morehouse, Chris ;

Pulkstenis, Erik ;

Drappa, Jorn ;

van der Merwe, Rene ;

Gasser, Robert A., Jr. .

GASTROENTEROLOGY, 2017, 153 (01) :77-+

[6]

Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2; randomised; double-blind; placebo-controlled trial.[J].Séverine Vermeire;William J Sandborn;Silvio Danese;Xavier Hébuterne;Bruce A Salzberg;Maria Klopocka;Dino Tarabar;Tomas Vanasek;Milo? Gregu?;Paul A Hellstern;Joo Sung Kim;Miles P Sparrow;Kenneth J Gorelick;Michelle Hinz;Alaa Ahmad;Vivek Pradhan;Mina Hassan-Zahraee;Robert Clare;Fabio Cataldi;Walter Reinisch.The Lancet.2017, 1009

[7]

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials [J].

Panes, Julian ;

Sandborn, William J. ;

Schreiber, Stefan ;

Sands, Bruce E. ;

Vermeire, Severine ;

D'Haens, Geert ;

Panaccione, Remo ;

Higgins, Peter D. R. ;

Colombel, Jean-Frederic ;

Feagan, Brian G. ;

Chan, Gary ;

Moscariello, Michele ;

Wang, Wenjin ;

Niezychowski, Wojciech ;

Marren, Amy ;

Healey, Paul ;

Maller, Eric .

GUT, 2017, 66 (06) :1049-1059

[8]

The safety of vedolizumab for ulcerative colitis and Crohn's disease [J].

Colombel, Jean-Frederic ;

Sands, Bruce E. ;

Rutgeerts, Paul ;

Sandborn, William ;

Danese, Silvio ;

D'Haens, Geert ;

Panaccione, Remo ;

Loftus, Edward V., Jr. ;

Sankoh, Serap ;

Fox, Irving ;

Parikh, Asit ;

Milch, Catherine ;

Abhyankar, Brihad ;

Feagan, Brian G. .

GUT, 2017, 66 (05) :839-851

[9]

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study [J].

Feagan, Brian G. ;

Sandborn, William J. ;

D'Haens, Geert ;

Panes, Julian ;

Kaser, Arthur ;

Ferrante, Marc ;

Louis, Edouard ;

Franchimont, Denis ;

Dewit, Olivier ;

Seidler, Ursula ;

Kim, Kyung-Jo ;

Neurath, Markus F. ;

Schreiber, Stefan ;

Scholl, Paul ;

Pamulapati, Chandrasena ;

Lalovic, Bojan ;

Visvanathan, Sudha ;

Padula, Steven J. ;

Herichova, Ivona ;

Soaita, Adina ;

Hall, David B. ;

Bocher, Wulf O. .

LANCET, 2017, 389 (10080) :1699-1709

[10]

Safety and Efficacy of ABT-494 (Upadacitinib); an Oral Jak1 Inhibitor; as Induction Therapy in Patients with Crohn's Disease: Results from Celest.[J].William J. Sandborn;Brian G. Feagan;Julian Panes;Geert R. D'Haens;Jean Frederic Colombel;Qian Zhou;Bidan Huang;Jeffrey V. Enejosa;Aileen L. Pangan;Ana P. Lacerda.Gastroenterology.2017, 5S1

← 1 2 3 →